aa 410090

Galectin-1 Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 15 kDa and the accession number is P16045.

Galectin-1 Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 15 kDa and the accession number is A0A384MR27.

LGALS3 (Galectin 3) is a Protein Coding gene. This gene encodes a member of the galectin family of carbohydrate-binding proteins. The encoded protein is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. LGALS3 is a beta-galactoside-binding lectin and plays a role in numerous cellular functions including apoptosis, innate immunity, cell adhesion, and T-cell regulation. LGALS3 has an important role in tumor progression through inhibition of apoptosis. LGALS3 expression is associated with neoplastic transformation and with differentiation of monocytes to macrophages. Elevated expression of LGALS3 has been demonstrated in the synovium of rheumatoid arthritis (RA). Diseases associated with LGALS3 include Follicular Adenoma and Papillary Carcinoma.

Galectin-1 is a member of growing family of evolutionary conserved animal lectins. Galectin-1 is widely expressed in many cells and tissues. Galectins consists of a Galectin domain and two Beta-galactoside binding domains. Galectin-1 can binds LGALS3BP and interacts with CD2, CD3, CD4, CD7, CD43 and CD45. Galectin-1 may act as an autocrine negative growth factor which regulates apoptosis, cell proliferation and cell differentiation. In addition, Galectin-1 plays improtant roles in immunosuppressive and antiinflammatory properties.

Galectin-3(LGALS3) is also known as Galactose-specific lectin 3, Mac-2 antigen, Carbohydrate-binding protein 35, Laminin-binding protein and Galactoside-binding protein. LGALS3 is highly expressed in early stages of papillary carcinoma, and lowly during tumor progression. LGALS3 is probably forms homo- or heterodimers and secreted by a non-classical secretory pathway and associates with the cell surface. LGALS3 plays an important role during the acquisition of vasculogenic mimicry and angiogenic properties. LGLAS3 takes part in an immune regulator to inhibit T-cell immune responses and promote tumor growth, as a result providing a new mechanism for tumor immune tolerance.

Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape.

Galectin-1 Protein, Rat, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 14.9 kDa and the accession number is P11762.

Galectin-1 Protein, Human, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 16.07 kDa and the accession number is NP_002296.1.

Galectin 1 (Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape.